Portal de Periódicos da CAPES

Treatment of refractory depression

1997; Wiley; Volume: 5; Issue: 4 Linguagem: Inglês

10.1002/(sici)1520-6394(1997)5

1520-6394

J. Craig Nelson,

Treatment of Major Depression

Depression and AnxietyVolume 5, Issue 4 p. 165-174 Research Article Treatment of refractory depression J. Craig Nelson M.D., Corresponding Author J. Craig Nelson M.D. Yale University School of Medicine, New Haven, CTYale-New Haven Hospital, 20 York St, New Haven, CT 06504.Search for more papers by this author J. Craig Nelson M.D., Corresponding Author J. Craig Nelson M.D. Yale University School of Medicine, New Haven, CTYale-New Haven Hospital, 20 York St, New Haven, CT 06504.Search for more papers by this author First published: 07 December 1998 https://doi.org/10.1002/(SICI)1520-6394(1997)5:4 3.0.CO;2-CCitations: 7AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Abstract Treatment of refractory depression is a common challenge for mental health professionals. To assure optimal treatment, the clinician should first determine that adequate dosage has been employed for an adequate duration. Next there are a variety of augmentation strategies or alternative antidepressants that could be considered. This report reviews the evidence supporting these strategies, describes their implementation, compares their effectiveness, and offers suggestions for approaching the array of treatments available. Depression and Anxiety 5:165–174, 1997. © 1997 Wiley-Liss, Inc. References Apter JT, Thase ME, Birkett M (1986) Fluoxetine treatment in depressed patients who failed treatment with sertraline. Presented at the American Society of Clinical Psychopharmacology Present's Day Educational Program, Montego Bay, Jamaica, February 18. Artigas F, Perez V, Alvarez E (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51: 248– 251. Artigas F, Romero L, deMontigny C, Blier P (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19: 378– 383. Ayd FJ, Jr, Zohar J (1987) Psychostimulant (amphetamine or methylphenidate) therapy for chronic and treatment-resistant depression. In J Zohar, RH Belmaker (eds): Treating Resistant Depression. New York: PMA Publishing, pp 343– 355. Bakish D (1991) Fluoxetine potentiation by buspirone: Three case histories. Can J Psychiatry 36: 749– 750. Beasley CM, Jr, Sayler ME, Cunningham GE, Weiss AM, Masica DN (1990) Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 20: 193– 200. Berman RM, Darnell AM, Miller HL, Charney DS (1995) Double-blind placebo-controlled trial of pindolol in depression. Presented at the Annual Meeting of the APA, May 22. Berman RM, Narasimhan M, Charney DS (1997) Treatment refractory depression: Definitions and characteristics. Anxiety and Depression 5: 154– 164. Blier P, Bergeron R (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15: 217– 222. Blier P, deMontigny C, Chaput Y (1987) Modification of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression. J Clin Psychopharmacol 7: 24S– S. Bodkin JA, Lasser RA, Wines JD, Gardner DM, Baldessarini RJ (1997) Combinign serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 58: 137– 145. Boyer WF, Feighner JP (1995) The combined use of fluoxetine and bupropion. Presented at the Annual Meeting of the APA, May 27. Brown WA, Harrison W (1992) Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull 28: 253– 256. Charney DS, Price LH, Heninger GR (1986) Desipramine-yohimbine combination treatment of refractory depression. Arch Gen Psychiatry 43: 1155– 1161. Cournoyer G, deMontigny D, Ouellette J, Leblanc G, Langlois R, Elie R (1984) Lithium addition in tricyclic-resistant unipolar depression: A placebo-controlled study. Collegium Internationale Neuro Psychopharmacologicum 14th CINP Congress, June 19- 23, Florence, Italy. Delgado PL, Price LH, Charney DS, Heninger GR (1988) Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 15: 55– 60. deMontigny C, Aghajanian GK (1978) Tricyclic antidepressants: Long-term treatment increases responsivity rat forebrain neurons to serotonin. Science 202: 1303– 1306. deMontigny C, Cournayer G, Morissetle R, Langlois R, Caillé G (1983) Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Arch Gen Psychiatry 40: 1327– 1334. deMontigny C, Debonnel G, Bergeon R, St-Andre E, Blier P (1995) Venlafaxine in treatment-resistant depression: An open-label multicenter study. Presented at the Annual Meeting of the American College of Neuropharmacology, Dec. 11, San Juan, Puerto Rico. deMontigny C, Grunberg F, Mayer A. Deschenes JP (1981) Lithium induces rapid relief of depression in tricyclic antidepressant drug nonresponders. Br J Psychiatry 138: 252– 256. Devlin MJ, Walsh BT (1990) use of monoamine oxidase inhibitors in refractory depression. In A Tasman, SM Goldfinger, CA Kaufman (eds): American Psychiatric Press Review of Psychiatry, vol 9. Washington, DC: American Psychiatric Press, pp 74– 90. Drimmer EJ, Gitlin MJ, Gwirtsman HE (1983) Desipramine and methyphenidate combination treatment for depression: Case report. Am J Psychiatry 140: 241– 242. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR (1991) CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 11: 127– 132. Gitlin MJ, Weiner H, Fairbanks L, Hershman JM, Friedfeld N (1987) Failure of T3 to potentiate tricyclic antidepressant response. J Affect Disord 13: 267– 272. Goldberg RS, Thornton WE (1978) Combined tricyclic-MAOI therapy for refractory depression: A review, with guidelines for appropriate usage. J Clin Pharmacol 18: 143– 147. Goodwin FK, Prange AJ, Post RM, Muscettola G, Lipton MA (1982) Potentiation of antidepressant effects by L-triiodotyronine in tricyclic nonresponders. Am J Psychiatry 139: 34– 38. Heninger FR, Charney DS, Sternberg DE (1983) Lithium carbonate augmentation of antidepressant treatment: An effective prescription for treatment-refractory depression. Arch Gen Psychiatry 40: 1335– 1342. Jacobsen RM (1991) Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 52: 217– 220. Joffe RT (1992) Triiodothyronine potentiation of fluoxetine in depressed patients. Can J Psychiatry 37: 48– 50. Joffe RT (1992) Triiodothyronine potentiation of fluoxetine in depressed patients. Can J Psychiatry 37: 48– 50. Joffe RT, Levitt AJ, Bagby RM, MacDonald C, Singer W (1993) Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic nonresponders. Br J Psychiatry 163: 574– 578. Joffe RT, Levitt AJ, Sokolov STH, Young LT (1996) Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 57: 114– 115. Joffe RT, Schuller DR (1993) An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 54: 269– 271. Joffe RT, Singer W (1990) A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressant. Psychiatry Res 32: 241– 251. Joffe RT, Singer W, Levitt AJ, MacDonald C (1993) A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 50: 387– 393. Joffe RT, Sokolov STH (1994) Thyroid hormones, the brain, the affective disorders. Crit Rev Neurobiol 8: 45– 63. Jones JS, Stanley M (1990) Serotonergic agents in the treatment of refractory depression. In SP Roose, AH Glassman (eds): Treatment Strategies for Refractory Depression. Washington, DC: American Psychiatric Press, Inc., pp 143– 167. Kantor D, McNevin S, Leichner P, Harper D, Krenn M (1986) The benefit of lithium carbonate adjunct in refractory depression: Fact or fiction? Can J Psychiatry 31: 416– 418. Katona CLE, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DRL, Lock T, Burns RA, Robertson MM (1995) Placebo-controlled trial of lithium augmentation if fluoxetine and lofepramine. Br J Psychiatry 166: 80– 86. Lader M (1983) Combined use of tricyclic antidepressants and monoamine oxidase inhibitors. J Clin Psychiatry 44: 20– 24. McGrath PJ, Stewart JW, Harrison W, Quitkin F (1987) Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 23: 169– 172. Nelson JC (1990) Use of lithium augmentation in refractory depression. In S Roose, A Glassman (eds) Treatment Strategies in Refractory Depression. Washington, DC: American Psychiatric Press, Inc., pp 35– 49. Nelson JC (1993) Combined treatment strategies in psychiatry. J Clin Psychiatry 54[9 suppl]: 42– 49. Nelson JC. Augmentation strategies for treatment of unipolar major depression. In AJ Rush (ed): Modern Problems of Pharmacology. New York: Basel Karger, in press. Nelson JC, Mazure C (1986) Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry 143: 363– 366. Nelson JC, Mazure CM, Bowers MB, Jatlow PI (1991) A preliminary open study of the combination of fluoxetine and de-sipramine for rapid treatment of major depression. Arch Gen Psychiatry 48: 303– 307. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J (1994) Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 14: 419– 423. Nierenberg AA, Price LH, Charney DS, Heninger GR (1990) After lithium augmentation: A retrospective follow-up of patients with antidepressant-refractory depression. J Affect Disord 18: 167– 175. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Haffmans J (1988a) Treatment strategy in depression: II. MAO inhibitors in depression resistant to cyclic antide-pressants. Acta Psychiatry Scand 78: 676– 683. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Haffmans J (1988b) Treatment strategy in depression: I. Non-tricyclic and selective reuptake inhibitors in resistant depression: A double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatry Scand 78: 668– 675. Ontiveros A, Fontaine R, Elie R (1991) Refractory depression: The addition of lithium to fluoxetine or desipramine. Acta Psychiatry Scan 83: 188– 192. Oppenheim G, Zohar J, Shapiro B, Belmaker RH (1987) The role of estrogen in treating resistant depression. In J Zohar, RH Belmaker (eds): Treating Resistant Depression. New York: PMA Publishing, pp 357– 366. Pare CMB (1963) Potentiation of monoamine-oxidase inhibitors by tryptophan. Lancet 7: 527– 528. Pare CMB, Mousawi MA, Sandler M, Glover V (1985) Attempts to attenuate the "cheese effect": Combined drug therapy in depressive illness. J Affect Disord 9: 137– 141. Peselow ED, Filippi AM, Goodnick P, Barouche F, Fieve RR (1989) The short and long term efficacy of paroxetine HCl: B. Data from a double-blind crossover study and from a year long trial vs. imipramine and placebo. Psychopharmacol Bull 25: 272– 276. Prange AJ, Wilson IC, Rabon AM, Lipton MA (1969) Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 126: 457– 469. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14: 90– 98. Preskorn SH, Beber JH, Faul JC, Hirschfeld RMA (1990) Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am J Psychiatry 147: 532. Price LH, Charney DS, Heninger G (1986) Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 143: 1387– 1392. Price LH, Charney DS, Heninger GR (1987) Reserpine augmentation of desipramine in refractory depression: Clinical and neuro-biological effects. Psychopharmacol 431: 437. Price LH, Charney DSM, Delgado PL, Heninger GR (1990) Fenfluramine augmentation in tricyclic-refractory depression. J Clin Psychopharmacol 10: 312– 317. Prudic J, Sackeim HA, Devanand DP (1990) Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res 31: 287– 296. Reimherr FW, Wood DR, Byerly B, Brainard J, Grosser BI (1984) Characteristics of responders to fluoxetine. Psychopharmacol Bull 20: 70– 72. Roose S (1990) Methodological issues in the diagnosis, treatment, and study of refractory depression. In S Roose, A Glassman (eds): Treatment Strategies in Refractory Depression. Washington, DC: American Psychiatric Press, Inc., pp 3– 9. Satel SL, Nelson JC (1989) Stimulants in the treatment of depression: A critical overview. J Clin Psychiatry 50: 241– 249. Schopf J, Baumann P, Lemarchand T, Rey M (1989) Treatment of endogenous depression-resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. Pharmacopsychiat 22: 183– 187. Schuckit M, Robins E, Feighner J (1971) Tricyclic antidepressants and monoamine oxidase inhibitors: Combination therapy in the treatment of depression. Arch Gen Psychiatry 24: 509– 514. Seth R, Jennings AL, Bindman J, et al. (1992) Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 161: 562– 565. Stein D, Avni J (1988) Thyroid hormones in the treatment of affective disorders. Acta Psychiatry Scan 77: 623– 636. Stein G, Bernadt M (1993) Lithium augmentation therapy in tricyclic-resistant depression: A controlled trial using lithium in low and normal doses. Br J Psychiatry 162: 634– 640. Stern WC, Harto-Truax N, Bauer N (1983) Efficacy of bupropion in tricyclic-resistant or intolerant patients. J Clin Psychiatry 44: 148– 152. Stoll AL, Pillay S, Diamond L, Workum AB, Cole JO (1996) Methylphenidate augmentation of serotonin selective reuptake inhibitors: A case series. J Clin Psychiatry 57: 72– 76. Thase ME, Kupfer DJ, Frank E, Jarrett DB (1989) Treatment of imipramine-resistant recurrent depression: II. An open clinical trial of lithium augmentation. J Clin Psychiatry 50: 413– 417. Thase ME, Kupfer DJ, Jarrett DB (1989) Treatment of imi-pramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine. J Clin Psychiatry 50: 385– 388. Thase ME, Malinger AG, McKnight D, Himmelhoch JM (1992) Treatment of imipramine-resistant recurrent depression: IV. A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 149: 195– 198. Tome MB, Isaac MT, Harte R, Holland C (1997) Paroxetine and pindolol: A randomised trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin. Psychopharmacol (in press). Wharton RN, Perel JM, Dayton PG, Malitz S (1971) A potential clinical use of methylphenidate with tricyclic antidepressants. Am J Psychiatry 127: 55– 61. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K (1989) Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report. J Clin Psychiatry 50: 447– 449. Young JPR, Lader MH, Hughes WC (1979) Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J 2: 1315– 1317. Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO (1996) Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline. J Clin Psychiatry 57: 67– 71. Zusky PM, Biederman J, Rosenbaum JF, Manschreck TC, Gross CC, Weilberg JB, Gastfriend DR (1988) Adjunct low dose lithium carbonate in treatment-resistant depression: A placebo-controlled study. J Clin Psychopharmacol 8: 120– 124. Citing Literature Volume5, Issue41997Pages 165-174 ReferencesRelatedInformation